Brian Hutcheson
Primary Podiatric Medicine · Tucson, AZNPI 1902978075
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Nevro Corp. at 31.9% of the total. Reporting peaked in 2024 at $337 and has fallen 69.5% since, to $103 in 2025.
Across 60 payments — averaging $15.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$288
- Kowa Pharmaceuticals America, Inc.$181
- Smith+Nephew$123
- Organogenesis Inc.$99
- Orthofix Medical, Inc.$71
- Globus Medical$65
- plus $75 from 4 others
What the payments were for
- Food & beverage$902100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 8 | $288 |
| Kowa Pharmaceuticals America, Inc. | 24 | $181 |
| Smith+Nephew | 6 | $123 |
| Organogenesis Inc. | 5 | $99 |
| Orthofix Medical, Inc. | 9 | $71 |
| Globus Medical | 4 | $65 |
| Bard Peripheral Vascular, Inc. | 1 | $22 |
| Biotissue Holdings Inc. | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Integra Lifesciences Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza$128
How this compares
Too few primary podiatric medicine providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 18 | $396 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 45 | $323 |
| Cephalexin | 33 | $265 |
| Gabapentin | 35 | $219 |
| Mupirocin | 13 | $120 |
| Amoxicillin | 11 | $29 |
Paid to pharmacies, not to this prescriber.
Other primary podiatric medicine in Tucson
- Zeno PfauTucson$5K
- Warren JosephPhoenix$529K
- David CorcoranPhoenix$4K
- Naresh DugalScottsdale$3K
- Ronaldo HolgadoSurprise$2K
- Ruth KosakScottsdale$333
- Jean KroynCottonwood$306
- Stephen GellerPhoenix$78
- Phillip TutnauerPinon$36
- Sanford KanerSurprise$20
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.